REFERENCES

Carter, Rob, Robin Marks, and David Hill. 1999. Could a national skin cancer primary prevention campaign in Australia be worthwhile?: An economic perspective. Health Prom Int 14:73-82.

Cutler, D.M. 1995. Technology, Health Costs, and the NIH, Harvard University and the National Bureau of Economic Research. Paper prepared for the National Institutes of Health Economics Roundtable on Biomedical Research, September 1995.

Cutler, David M., Mark McClellan, Joseph P. Newhouse, and Dahlia Remler. 1998. Are medical prices falling? Quarterly Journal of Economics 113(4):991-1024

Cutler, David M., and Elizabeth Richardson. 1999. Your money and your life: The value of health and what affects it. In Alan Garber, ed., Frontiers in Health Policy Research, Volume 2, pp. 99-132.

Cutler, David M. Forthcoming. Better Medicine.


Dubois, Robert W., Anita J. Chawla, Cheryl A. Neslusan, Mark W. Smith, and Sally Wade. 2000. Explaining drug spending trends: Does perception match reality? Health Affairs 19(2): 231-239.


Freedberg, Kenneth A., Alan C. Geller, Donald R. Miller, Robert A. Lew, and Howard K. Koh. 1999. Screening for malignant melanoma: A cost-effectiveness analysis. J. Am. Acad. Dermatol. 41:738.


Hillner, Bruce E., John M. Kirkwood, and Sanjiv S. Agarwala. 2001. Burden of illness associated with metastatic melanoma: An audit of 100 consecutive referral center cases. Cancer 91(9):1814-1821.


IMS Health. 2001. Pharmaceutical Pricing Update. Vol. 8. No. 4. (June 2001). Plymouth Meeting, PA.


Kessler, R.C., P.E. Greenberg, K.D. Mickelson, L.M. Meneades, and P.S Wang. 2001. The effects of chronic medical conditions on work loss and work cutback. Journal of Occupational and Environmental Medicine. 43(Suppl. 3):218-225.


Lasker Foundation. 2000. Exceptional Returns: The Economic Value of America’s Investment in Medical Research. New York, NY.

Lichtenberg, Frank R. 1996. Do (more and better) drugs keep people out of hospital? American Economic Review (May):384-388.

Lichtenberg, Frank R. 2001. Are the benefits of newer drugs worth their cost? Evidence from the 1996 MEPS. Health Affairs 20(5):241-251.


Newhouse, J.P. 1992. Medical care costs: How much welfare loss? Journal of Economic Perspectives 6(3):3-21.


Rosenberg, Steven A. 2001. Progress in human tumour immunology and immunotherapy. Nature 411:380-384.


Tamura, Yasuaki, Ping Peng, Kang Liu, Maria Daou, and Pramod K. Srivastava. 1997. Immonotherapy of tumors with autologous tumor-derived heat shock protein preparations. Science 278(5335):117-120.

Tolley, George, Donald Kenkel, and Robert Fabian, eds. 1994. Valuing Health for Policy: An Economic Approach. Chicago: The University of Chicago Press.

Topel, Robert H., and Kevin M. Murphy. Forthcoming. The Economic Value of Medical Knowledge. In Exceptional Returns, Robert H. Topel and Kevin M. Murphy, eds. Chicago: University of Chicago Press.


Viscusi, W. Kip. 1993. The value of risks to life and health. Journal of Economic Literature, 31(4):1912-1946.


Washington Post editorial. June 9, 2001. Back to health care costs.



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement